

ABSTRACT

The use of interleukin 7 or T cells pre-incubated in the presence of IL-7 for preparing a drug or pharmaceutical composition for treating an auto-immune disease, particularly an 5 auto-immune disease induced by a defect in CD4+ T cell immunoregulation, is disclosed.